Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.
Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.
LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.
Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.
LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.
For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.
LeMaitre (Nasdaq:LMAT) reported Q4 2022 results showing a 4% increase in sales to $41.0 million, with organic sales growth of 8%. Operating income fell 16% to $7.0 million, while net income declined 9% to $5.6 million, resulting in earnings per share of $0.25. The gross margin decreased to 63.6% due to a strong dollar. The company announced a quarterly dividend of $0.14/share (+12%) and provided optimistic guidance for Q1 2023, expecting sales of $42.6 million to $45.0 million (+11%). Full-year sales guidance is projected at $174.3 million to $178.3 million (+9%). A stock repurchase program of $25 million was also authorized.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will announce its fourth quarter 2022 financial results on February 23, 2023, after market close. Following the release, a conference call is scheduled for 5:00 PM ET to discuss the results, business highlights, and outlook for the company. LeMaitre specializes in devices, implants, and services for treating peripheral vascular diseases affecting over 200 million globally. The company's portfolio addresses the needs of vascular surgeons, with a focus on disposable and implantable vascular devices.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two significant investor conferences. David Roberts, President, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 3:10 PM ET in New York City. Additionally, he will present at the Sidoti Small-Cap Virtual Conference on December 8, 2022, at 1:15 PM ET. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million individuals globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in two investor conferences. David Roberts, President, will present at the Stifel Healthcare Conference on November 15, 2022, at 3:00 PM ET in New York City. Additionally, CFO JJ Pellegrino will host 1x1 meetings at the Canaccord Genuity Forum on November 17, 2022, also in New York City.
LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million people globally. More details are available at www.lemaitre.com.
LeMaitre (Nasdaq:LMAT) reported Q3 2022 results with sales of $39.0 million, a 2% increase year-over-year. Operating income fell 32% to $6.2 million with a margin of 16%. Net income decreased 16% to $5.5 million, with earnings per share at $0.25, down 17%. Sales growth was driven by carotid shunts (+23%) and other products. The company also announced a quarterly dividend of $0.125 per share, payable December 1, 2022. Guidance for Q4 2022 estimates sales of $39.8-$42.2 million and expects a gross margin of 65.8%. Cash and investments rose by $4.1 million to $79.7 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2022 financial results on October 27, 2022, after market close. A conference call is scheduled for 5:00 PM ET that same day to discuss the results, business highlights, and outlook. LeMaitre specializes in devices for peripheral vascular disease, which affects over 200 million people globally. The company manufactures and markets disposable and implantable vascular devices tailored for vascular surgeons.
BURLINGTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that President David Roberts will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. This event is scheduled for September 14, 2022, at 4:40 PM ET, taking place at the Sheraton New York Hotel.
LeMaitre Vascular specializes in devices and services for peripheral vascular disease, impacting over 200 million globally, offering solutions tailored for vascular surgeons.
LeMaitre Vascular (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 12:00 PM ET in Boston. The company focuses on devices, implants, and services for treating peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices aimed at the needs of vascular surgeons. For more details, visit lemaitre.com.
LeMaitre (LMAT) reported Q2 2022 sales of $42.1 million, up 4% year-over-year. Gross margin increased to 66.0%. However, operating income fell 48% to $5.8 million, and EPS declined by 60% to $0.16. The company announced a quarterly dividend of $0.125/share and increased guidance for 2022 to 10% organic growth. Key growth drivers included biologics, especially XenoSure (+21%).
The company closed its St. Etienne factory, incurring a $3.1 million special charge.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q2 2022 financial results on July 28, 2022, after market close. The company has scheduled a conference call at 5:00 PM ET the same day to discuss the results, business highlights, and future outlook. LeMaitre specializes in developing and marketing devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.
FAQ
What is the current stock price of LeMaitre Vascular (LMAT)?
What is the market cap of LeMaitre Vascular (LMAT)?
What products does LeMaitre Vascular offer?
Where is LeMaitre Vascular headquartered?
In which medical areas are LeMaitre's products primarily used?
What was the company's financial performance in Q3 2023?
How does LeMaitre Vascular engage with its investors?
What regions contribute significantly to LeMaitre's revenue?
Does LeMaitre Vascular pay dividends to its shareholders?
What recent financial achievements has LeMaitre Vascular reported?
How does LeMaitre ensure the quality of its products?
Where can I find more information about LeMaitre Vascular?
